\babel@toc {english}{}
\contentsline {chapter}{\numberline {1}Transcription}{4}{chapter.1}% 
\contentsline {section}{\numberline {1.1}Recap on transcription}{4}{section.1.1}% 
\contentsline {section}{\numberline {1.2}2- Transcriptional Control in Cancer}{4}{section.1.2}% 
\contentsline {subsection}{\numberline {1.2.1}Transcription initiation}{4}{subsection.1.2.1}% 
\contentsline {subsection}{\numberline {1.2.2}Chromatin remodeling}{6}{subsection.1.2.2}% 
\contentsline {subsubsection}{\numberline {1.2.2.1}Techniques to study chromatin remodelling}{6}{subsubsection.1.2.2.1}% 
\contentsline {subsection}{\numberline {1.2.3}Nucleosome organization}{7}{subsection.1.2.3}% 
\contentsline {subsubsection}{\numberline {1.2.3.1}Nucleosome remodelling}{7}{subsubsection.1.2.3.1}% 
\contentsline {section}{\numberline {1.3}3 (1)}{8}{section.1.3}% 
\contentsline {subsection}{\numberline {1.3.1}Main nucleosome modifications in promoters:}{9}{subsection.1.3.1}% 
\contentsline {subsubsection}{\numberline {1.3.1.1}RT-qPCR based detection of 5' RNA transcripts of inactive genes}{9}{subsubsection.1.3.1.1}% 
\contentsline {subsubsection}{\numberline {1.3.1.2}Global run-on sequencing (GRO-seq)}{10}{subsubsection.1.3.1.2}% 
\contentsline {subsubsection}{\numberline {1.3.1.3}Transcription pausing mechanism}{12}{subsubsection.1.3.1.3}% 
\contentsline {section}{\numberline {1.4}4 - TCiC (1)}{13}{section.1.4}% 
\contentsline {subsection}{\numberline {1.4.1}Structural basis of the nucleosome transition during RNA pol II passage - Kujirai et al 2018}{13}{subsection.1.4.1}% 
\contentsline {subsubsection}{\numberline {1.4.1.1}Nucleosome structure}{13}{subsubsection.1.4.1.1}% 
\contentsline {subsubsection}{\numberline {1.4.1.2}Cryo-EM}{13}{subsubsection.1.4.1.2}% 
\contentsline {subsubsection}{\numberline {1.4.1.3}Summary of the main results}{15}{subsubsection.1.4.1.3}% 
\contentsline {subsubsection}{\numberline {1.4.1.4}Template looping}{15}{subsubsection.1.4.1.4}% 
\contentsline {subsubsection}{\numberline {1.4.1.5}Structural basis of nucleosome disassembly and reassembly by RNA P II elongation complex with FACT - Ehara et al.}{16}{subsubsection.1.4.1.5}% 
\contentsline {section}{\numberline {1.5}Termination}{17}{section.1.5}% 
\contentsline {subsubsection}{\numberline {1.5.0.1}Promoter reporter assay}{17}{subsubsection.1.5.0.1}% 
\contentsline {subsubsection}{\numberline {1.5.0.2}\textbf {Promoter types}}{18}{subsubsection.1.5.0.2}% 
\contentsline {subsubsection}{\numberline {1.5.0.3}Transcription factor binding}{19}{subsubsection.1.5.0.3}% 
\contentsline {chapter}{\numberline {2}Enhancer regulation}{21}{chapter.2}% 
\contentsline {section}{\numberline {2.1}5 - TCiC (1)}{21}{section.2.1}% 
\contentsline {subsubsection}{\numberline {2.1.0.1}Mediator complex}{21}{subsubsection.2.1.0.1}% 
\contentsline {subsection}{\numberline {2.1.1}Wnt signalling pathway}{23}{subsection.2.1.1}% 
\contentsline {subsubsection}{\numberline {2.1.1.1}$\beta $ -catenin structure}{24}{subsubsection.2.1.1.1}% 
\contentsline {subsubsection}{\numberline {2.1.1.2}\textbf {The canonical Wnt/$\beta $ -catenin pathway is crucially involved in colorectal cancer}}{25}{subsubsection.2.1.1.2}% 
\contentsline {section}{\numberline {2.2}6- Transcriptional Control in Cancer}{27}{section.2.2}% 
\contentsline {section}{\numberline {2.3}CREP/p300}{27}{section.2.3}% 
\contentsline {subsubsection}{\numberline {2.3.0.1}CREP/p300 structure}{27}{subsubsection.2.3.0.1}% 
\contentsline {subsection}{\numberline {2.3.1}\textbf {TSSa-RNAs transcription}}{29}{subsection.2.3.1}% 
\contentsline {subsubsection}{\numberline {2.3.1.1}Properties of eRNAs}{30}{subsubsection.2.3.1.1}% 
\contentsline {subsubsection}{\numberline {2.3.1.2}\textbf {Assessing whether the CRC 8q24 risk region acts as an enhancer}}{31}{subsubsection.2.3.1.2}% 
\contentsline {chapter}{\numberline {3}Chromsome domains and oncogene activation}{33}{chapter.3}% 
\contentsline {section}{\numberline {3.1}7- Transcriptional Control in Cancer}{33}{section.3.1}% 
\contentsline {subsubsection}{\numberline {3.1.0.1}Cohesin mediates transcriptional insulation by CCCTC-binding factor}{37}{subsubsection.3.1.0.1}% 
\contentsline {subsubsection}{\numberline {3.1.0.2}Chromosome Conformation Capture (3C)}{40}{subsubsection.3.1.0.2}% 
\contentsline {subsubsection}{\numberline {3.1.0.3}Hi-C approach}{40}{subsubsection.3.1.0.3}% 
\contentsline {subsubsection}{\numberline {3.1.0.4}Optimization of Hi-C approach}{42}{subsubsection.3.1.0.4}% 
\contentsline {subsubsection}{\numberline {3.1.0.5}Promoter-Enhancer Communication Occurs Primarily within Insulated neighbourhoods}{45}{subsubsection.3.1.0.5}% 
\contentsline {subsection}{\numberline {3.1.1}Super-enhancers}{55}{subsection.3.1.1}% 
\contentsline {section}{\numberline {3.2}How is a SE generated during tumorigenesis?}{57}{section.3.2}% 
\contentsline {subsection}{\numberline {3.2.1}How cancer cells take advantage of super-enhancers}{61}{subsection.3.2.1}% 
\contentsline {section}{\numberline {3.3}The role of MYC in cancer cells}{63}{section.3.3}% 
\contentsline {subsection}{\numberline {3.3.1}Key aspect of MYC in tumorigenesis}{65}{subsection.3.3.1}% 
\contentsline {subsubsection}{\numberline {3.3.1.1}MYC transcription factor forms a heterodimer with MAX}{66}{subsubsection.3.3.1.1}% 
\contentsline {subsection}{\numberline {3.3.2}By which major mechanism or pathway MYC proteins promote tumorigenesis?}{70}{subsection.3.3.2}% 
\contentsline {chapter}{\numberline {4}TCIC}{71}{chapter.4}% 
\contentsline {section}{\numberline {4.1}13- Transcriptional Control in Cancer}{71}{section.4.1}% 
\contentsline {section}{\numberline {4.2}Targeting transcription in cancer}{71}{section.4.2}% 
\contentsline {subsubsection}{\numberline {4.2.0.1}Age-related remodellling of \textbf {oesophageal epithelia by mutated cancer drivers}}{71}{subsubsection.4.2.0.1}% 
\contentsline {subsubsection}{\numberline {4.2.0.2}Key points}{74}{subsubsection.4.2.0.2}% 
\contentsline {subsection}{\numberline {4.2.1}Target transcription in cancer}{76}{subsection.4.2.1}% 
\contentsline {section}{\numberline {4.3}15- Transcriptional Control in Cancer}{77}{section.4.3}% 
\contentsline {section}{\numberline {4.4}BRD4}{77}{section.4.4}% 
\contentsline {subsubsection}{\numberline {4.4.0.1}Selective inhibition of Tumor Oncogenes by Disruption of Super-Enhancers}{77}{subsubsection.4.4.0.1}% 
\contentsline {section}{\numberline {4.5}YAP/TAZ}{78}{section.4.5}% 
\contentsline {section}{\numberline {4.6}TEAD}{80}{section.4.6}% 
\contentsline {subsection}{\numberline {4.6.1}YAP/TAZ/TEAD}{80}{subsection.4.6.1}% 
\contentsline {section}{\numberline {4.7}17- Transcriptional Control in Cancer}{81}{section.4.7}% 
\contentsline {section}{\numberline {4.8}Nuclear receptors}{81}{section.4.8}% 
\contentsline {subsection}{\numberline {4.8.1}Estrogen receptor \(\alpha \)}{82}{subsection.4.8.1}% 
\contentsline {subsection}{\numberline {4.8.2}ER$\alpha $) in breast cancer}{82}{subsection.4.8.2}% 
\contentsline {subsubsection}{\numberline {4.8.2.1}Mechanisms provoking breast cancer drug resistance}{84}{subsubsection.4.8.2.1}% 
\contentsline {subsubsection}{\numberline {4.8.2.2}Summary}{84}{subsubsection.4.8.2.2}% 
\contentsline {subsubsection}{\numberline {4.8.2.3}ER$\alpha $ transcriptional program}{85}{subsubsection.4.8.2.3}% 
\contentsline {chapter}{\numberline {5}Genome instability}{87}{chapter.5}% 
\contentsline {section}{\numberline {5.1}19- Transcriptional Control in Cancer}{87}{section.5.1}% 
\contentsline {section}{\numberline {5.2}Transcription and genome instability}{87}{section.5.2}% 
\contentsline {subsection}{\numberline {5.2.1}R-loops}{87}{subsection.5.2.1}% 
\contentsline {subsubsection}{\numberline {5.2.1.1}R-loop degradation}{88}{subsubsection.5.2.1.1}% 
\contentsline {subsubsection}{\numberline {5.2.1.2}R-loop recognition and distribution}{88}{subsubsection.5.2.1.2}% 
\contentsline {subsubsection}{\numberline {5.2.1.3}VIM-antisense1}{89}{subsubsection.5.2.1.3}% 
\contentsline {subsubsection}{\numberline {5.2.1.4}Main findings}{90}{subsubsection.5.2.1.4}% 
\contentsline {subsection}{\numberline {5.2.2}HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia}{90}{subsection.5.2.2}% 
\contentsline {subsubsection}{\numberline {5.2.2.1}Conclusions}{92}{subsubsection.5.2.2.1}% 
\contentsline {subsection}{\numberline {5.2.3}HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice}{92}{subsection.5.2.3}% 
\contentsline {section}{\numberline {5.3}20- Transcriptional Control in Cancer}{92}{section.5.3}% 
\contentsline {section}{\numberline {5.4}Transcription and genome instability II}{92}{section.5.4}% 
\contentsline {subsection}{\numberline {5.4.1}DNA damage}{92}{subsection.5.4.1}% 
\contentsline {subsubsection}{\numberline {5.4.1.1}R loop modified bases}{93}{subsubsection.5.4.1.1}% 
\contentsline {subsection}{\numberline {5.4.2}Apical kinases}{93}{subsection.5.4.2}% 
\contentsline {subsection}{\numberline {5.4.3}Topoisomerases}{96}{subsection.5.4.3}% 
\contentsline {subsubsection}{\numberline {5.4.3.1}A topoisomerase IIb-mediated dsDNA break required for Regulated Transcription}{96}{subsubsection.5.4.3.1}% 
\contentsline {subsubsection}{\numberline {5.4.3.2}BRCA1}{97}{subsubsection.5.4.3.2}% 
\contentsline {subsubsection}{\numberline {5.4.3.3}Stark et al.}{97}{subsubsection.5.4.3.3}% 
\contentsline {chapter}{\numberline {6}DNA repair}{99}{chapter.6}% 
\contentsline {subsection}{\numberline {6.0.1}Biogenesis of canonical miRNA}{99}{subsection.6.0.1}% 
\contentsline {subsection}{\numberline {6.0.2}DICER and DROSH regulation of DDR and checkpoint enforcement}{101}{subsection.6.0.2}% 
\contentsline {subsection}{\numberline {6.0.3}DDRNAs}{101}{subsection.6.0.3}% 
\contentsline {subsubsection}{\numberline {6.0.3.1}DDRNAs and dilncRNAs regulate DDR and DNA repair}{103}{subsubsection.6.0.3.1}% 
\contentsline {subsection}{\numberline {6.0.4}RNA Pol II recruitment at DSBs}{104}{subsection.6.0.4}% 
